JPRN-jRCT2080223124已完成1 期
Phase I Clinical Study of ABI-007 in Combination with Gemcitabine as Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Has personally given written informed consent to participate in this clinical study
- •- Pancreatic adenocarcinoma histologically confirmed to be invasive ductal carcinoma
- •- Macroscopic examination shows that the primary pancreatic lesion has been completely resected
- •- Has undergone surgery for primary pancreatic tumor within 12 weeks before the start of study treatment
- •- Pancreatic cancer staging: T1-3, N0-1 and M0 by TNM classification (the seventh edition, proposed by UICC in 2009)
排除标准
- •- History of treatment other than surgery (chemotherapy, radiotherapy, etc.) for the primary pancreatic tumor
- •- Grade 2 or higher peripheral sensory or motor neuropathy
- •- As judged by the investigator (subinvestigator), ineligible for entry into the study
研究者
相似试验
未知
2 期
Phase II study of ABI-007 in combination with Ramucirumabnresectable/recurrent gastric cancer patients refractory to prior chemotherapy containing fluoropyrimidineJPRN-jRCT2080223034Taiho Pharmaceutical Co., Ltd.40
未知
1 期
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast CancerMetastatic breast cancerJPRN-jRCT2080221553Taiho Pharmaceutical Co., Ltd.24
已完成
2 期
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast CancerMetastatic Breast CancerNCT00394082Celgene50
终止
1 期
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)Acute Myelogenous LeukemiaMyelogenous LeukemiaTreatment Naive AMLNCT02203773AbbVie212
已完成
1 期
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)NCT02009332Aadi Bioscience, Inc.21